Transforming growth factor-β: Biology and clinical relevance

Journal of Biochemistry and Molecular Biology

Volumn 38, Issue 1, 2005, Pages 1-8

  Kim, Isaac Yi ^a   Kim, Moses M ^b   Kim, Seong Jin ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cell cycle; Signal; Smad; TGF ; Tumor suppressor; Wound healing

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

BIOLOGY; HUMAN; PHYSIOLOGY; REVIEW;

BIOLOGY; HUMANS; TRANSFORMING GROWTH FACTOR BETA;

EID: 21244443875     PISSN: 12258687     EISSN: 12258687     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Alexandrow, M. G., Kawabata, M., Aakre, M. and Moses, H. L. (1995) Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor β1. Proc. Natl. Acad. Sci. USA 92, 3239-3243.
2. Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M. and Forbes, J. T. (1993) Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J. Clin. Invest. 92, 2569-2576.
3. Ashcroft, G. S., Yang, X., Glick, A. B., Weinstein, M., Letterio, J. L., Mizel, D. E., Anzano, M., Greenwell-Wild, T., Wahl, S. M., Deng, C. and Roberts, A. B. (1999) Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat. Cell Biol. 1, 260-266.
4. Bernstein, E. F., Harisiadis, L., Salomon, G., Norton, J., Sollberg, S., Uitto, J., Glatstein, E., Glass, J., Talbot, T. and Russo, A. (1991) Transforming growth factor-beta improves healing of radiation-impaired wounds. J. Invest. Dermatol. 97, 430-434.
5. Bonniaud, P., Kolb, M., Galt, T., Robertson, J., Robbins, C., Stampfli, M., Lavery, C., Margetts, P. J., Roberts, A. B. and Gauldie, J. (2004) Smad3 null mice develop airspace enlargement and are resistant to TGF-β-mediated pulmonary fibrosis. J. Immunol. 173, 2099-2108.
6. Chang, J., Park, K., Bang, Y.-J., Kim, W. S., Kim, D. and Kim, S.-J. (1997) Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res. 57, 2856-2859.
7. Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A. and Blay, J. Y. (1997) The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18, 493-497.
8. Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven, L., Bruyneel, E., Mareel, M., Huylebroeck, D. and van Roy, F. (2001) The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 7, 1267-1278.
9. Cui, W., Fowlis, D. J., Bryson, S., Duffie, E., Ireland, H., Balmain, A. and Akhurst, R. J. (1996) TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86, 531-542.
10. Czaja, M. J., Weiner, F. R., Flanders, K. C., Giambrone, M. A., Wind, R., Biempica, L. and Zern, M. A. (1989) In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J. Cell Biol., 108, 2477-2482.
11. Datto, M. B., Li, Y., Panus, J. F., Howe, D. J., Xiong, Y. and Wang, X. F. (1995) Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA 92, 5545-5549.
12. de Caestecker, M. P., Piek, E. and Roberts, A. B. (2000) Role of transforming growth factor-β signaling in cancer. J. Natl. Cancer Inst. 92, 1388-1402.
13. Derynck, R., Akhurst, R. J. and Balmain, A. (2001) TGF-β signaling in tumor suppression and cancer progression. Nat. Genet. 29, 117-129.
14. Derynck, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S. and Berger, W. H. (1987) Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res. 47, 707-712.
15. Derynck, R. and Zhang, Y. E. (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature, 425, 577-584.
16. Ebisawa, T., Fukuchi, M., Murakami, G., Chiba, T., Tanaka, K., Imamura, T. and Miyazono, K. (2001) Smurf1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. 276, 12477-12480.
17. Ewen, M. E., Sluss, H. K., Whitehouse, L. L. and Livingston, D. M. (1993) TGF β inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell 74, 1009-1020.
18. Factor, V. M., Kao, C. Y., Santoni-Rugiu, E., Woitach, J. T., Jensen, M. R. and Thorgeirsson, S. S. (1997) Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice. Cancer Res. 57, 2089-2095.
19. Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., Mercola, D., Black, K. L., Royston, I. and Sobol, R. E. (1996) Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. USA 93, 2909-2914.
20. Flanders, K. C. (2004) Smad3 as a mediator of the fibrotic response. Int. J. Exp. Pathol. 85, 47-64.
21. Flanders, K. C., Sullivan, C. D., Fujii, M., Sowers, A., Anzano, M. A., Arabshahi, A., Major, C., Deng, C., Russo, A., Mitchell, J. B. and Roberts, A. B. (2002) Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J. Pathol. 160, 1057-1068.
22. Furukawa, F., Matsuzaki, K., Mori, S., Tahashi, Y., Yoshida, K., Sugano, Y., Yamagata, H., Matsushita, M., Seki, T., Inagaki, Y., Nishizawa, M., Fujisawa, J. and Inoue, K. (2003) p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 38, 879-889.
23. Gorelik, L. and Flavell, R. A. (2000) Abrogation of TGF â signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 12, 171-181.
24. Gorelik, L. and Flavell, R. A. (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat. Med. 7, 1118-1122.
25. Grady, W. M., Myeroff, L. L., Swinler, S. E., Rajput, A., Thiagalingam, S., Lutterbaugh, J. D., Neumann, A., Brattain, M. G., Chang, J., Kim, S. J., Kinzler, K. W., Vogelstein, B., Willson, J. K. and Markowitz, S. (1999) Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Res, 59, 320-324.
26. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371, 257-261.
27. Iavarone, A. and Massague, J. (1997) Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15. Nature 387, 417-422.
28. Inman, G. J., Nicolas, F. J. and Hill, C. S. (2002) Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-β receptor activity. Mol. Cell. 10, 283-294.
29. Itoh, S., Itoh, F., Goumans, M. J. and Ten Dijke, P. (2000) Signaling of transforming growth factor-â family members through Smad proteins. Eur. J. Biochem. 267, 6954-6967.
30. Jang, C. W., Chen, C. H., Chen, C. C., Chen, J. Y., Su, Y. H. and Chen, R. H. (2002) TGF-β induces apoptosis through Smad-mediated expression of DAP-kinase. Nat. Cell Biol. 4, 51-58.
31. Kavsak, P., Rasmussen, R. K., Causing, C. G., Bonni, S., Zhu, H., Thomsen, G. H. and Wrana, J. L. (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGFβ receptor for degradation. Mol. Cell. 6, 1365-1375.
32. Kim, B.-C., Lee, H.-J., Park, S. H., Lee, S., Karpova, T. S., McNally, J. G., Felici, A., Lee, D. K. and Kim. S.-J. (2004) Jab1/CSN5, a component of the COP9 signalosome, regulates transforming growth factor β signaling by binding to Smad7 and promoting its degradation. Mol. Cell. Biol. 24, 2251-2262.
33. Kim, S.-J., Im, Y.-H., Markowitz, S. D. and Bang, Y.-J. (2000) Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis. Cytokine Growth Factor Rev. 11, 159-168.
34. 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 90, 770-774.
35. Larisch, S., Yi, Y., Lotan, R., Kerner, H., Eimerl, S., Tony Parks, W., Gottfried, Y., Birkey Reffey, S., de Caestecker, M. P., Danielpour, D., Book-Melamed, N., Timberg, R., Duckett, C. S., Lechleider, R. J., Steller, H., Orly, J., Kim, S. J. and Roberts, A. B. (2000) A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif. Nat. Cell Biol. 2, 915-921.
36. Lu, S. L., Zhang, W. C., Akiyama, Y., Nomizu, T. and Yuasa, Y. (1996) Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Res. 56, 4595-4598.
37. Madri, J. A., Pratt, B. M. and Tucker, A. M. (1988) Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix. J. Cell Biol. 106, 1375-1384.
38. Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B. and et al. (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268, 1336-1338.
39. Martin, J. S., Dickson, M. C., Cousins, F. M., Kulkarni, A. B., Karlsson, S. and Akhurst, R. J. (1995) Analysis of homozygous TGF beta 1 null mouse embryos demonstrates defects in yolk sac vasculogenesis and hematopoiesis. Ann. N. Y. Acad. Sci. 752, 300-308.
40. Matthews, E., Yang, T., Janulis, L., Goodwin, S., Kundu, S. D., Karpus, W. J. and Lee, C. (2000) Down-regulation of TGF- β1 production restores immunogenicity in prostate cancer cells. Br. J. Cancer 83, 519-525.
41. Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S., Gotwals, P. J., Koteliansky, V. and Arteaga, C. L. (2002) Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109, 1551-1559.
42. Myeroff, L. L., Parsons, R., Kim, S.-J., Hedrick, L., Cho, K. R., Orth, K., Mathis, M., Kinzler, K. W., Lutterbaugh, J., Park, K., Bang, Y.-J., Lee, H. Y., Park, J.-G., Lynch. H. T., Roberts, A. B., Vogelstein, B. and Markowitz, S. D. (1995) A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 55, 5545-5547.
43. Nomura, M. and Li, E. (1998) Smad2 role in mesoderm formation, leftright patterning and craniofacial development. Nature 393, 786-790.
44. Oft, M., Heider, K. H. and Beug, H. (1998) TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol. 8, 1243-1252.
45. Oft, M., Peli, J., Rudaz, C., Schwarz, H., Beug, H. and Reichmann, E. (1996) TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10, 2462-2477.
46. Park, K., Kim, S.-J., Bang, Y.-J., Park, J.-G., Kim, N. K., Roberts, A. B. and Sporn, M. B. (1994) Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proc. Natl. Acad. Sci. USA 91, 8772-8776.
47. Pasche, B., Kolachana, P., Nafa, K., Satagopan, J., Chen, Y. G., Lo, R. S., Brener, D., Yang, D., Kirstein, L., Oddoux, C., Ostrer, H., Vineis, P., Varesco, L., Jhanwar, S., Luzzatto, L., Massague, J. and Offit, K. (1999). TβR-I(6A) is a candidate tumor susceptibility allele. Cancer Res. 59, 5678-5682.
48. Peinado, H., Quintanilla, M. and Cano, A. (2003) Transforming growth factor β-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J. Biol. Chem. 278, 21113-21123.
49. Pertovaara, L., Kaipainen, A., Mustonen, T., Orpana, A., Ferrara, N., Saksela, O. and Alitalo, K. (1994) Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J. Biol. Chem. 269, 6271-6274.
50. Plum, J., De Smedt, M., Leclercq, G. and Vandekerckhove, B. (1995) Influence of TGF-beta on murine thymocyte development in fetal thymus organ culture. J. Immunol. 154, 5789-5798.
51. Portella, G., Cumming, S. A., Liddell, J., Cui, W., Ireland, H., Akhurst, R. J. and Balmain, A. (1998) Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ. 9, 393-404.
52. Reynisdottir, I., Polyak, K., Iavarone, A. and Massague, J. (1995) Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev., 9, 1831-1845.
53. Roberts, A. B. and Sporn, M. B. (1990). Peptide growth factors and their receptors: Handbook of Experimental Pharmacology pp. 421-472. Springer-Verlag, Heidelberg, Germany.
54. Sandhu, C., Garbe, J., Bhattacharya, N., Daksis, J., Pan, C. H., Yaswen, P., Koh, J., Slingerland, J. M. and Stampfer, M. R. (1997) Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol. Cell Biol. 17, 2458-2467.
55. Sebzda, E., Mariathasan, S., Ohteki, T., Jones, R., Bachmann, M. F. and Ohashi, P. S. (1999) Selection of the T cell repertoire. Annu. Rev. Immunol. 17, 829-874.
56. Shah, A. H., Tabayoyong, W. B., Kim, S. Y., Kim, S. J., Van Parijs, L. and Lee, C. (2002a) Reconstitution of lethally irradiated adult mice with dominant negative TGF-β type II receptor-transduced bone marrow leads to myeloid expansion and inflammatory disease. J. Immunol. 169, 3485-3491.
57. Shah, A. H., Tabayoyong, W. B., Kundu, S. D., Kim, S. J., Van Parijs, L., Liu, V. C., Kwon, E., Greenberg, N. M. and Lee, C. (2002b) Suppression of tumor metastasis by blockade of transforming growth factor β signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res, 62, 7135-7138.
58. Shi, Y. and Massagué, J. (2003) Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685-700.
59. Siegel, P. M. and Massague, J. (2003) Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat. Rev. Cancer 3, 807-821.
60. Sun, L. and Chen, C. (1997) Expression of transforming growth Factor β type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J. Biol. Chem. 272, 25367-25372.
61. Surh, C. D. and Sprent, J. (1994) T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372, 100-103.
62. Tachibana, I., Imoto, M., Adjei, P. N., Gores, G. J., Subramaniam, M., Spelsberg, T. C. and Urrutia, R. (1997) Overexpression of the TGF β-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells. J. Clin. Invest. 99, 2365-2374.
63. Tang, J., Nuccie, B. L., Ritterman, I., Liesveld, J. L., Abboud, C. N. and Ryan, D. H. (1997) TGF-beta down-regulates stromal IL-7 secretion and inhibits proliferation of human B cell precursors. J. Immunol. 159, 117-125.
64. Thiery, J. P. (2002) Epithelialmesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442-454.
65. 1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 87, 1486-1490.
66. Tsukazaki, T., Chiang, T. A., Davison, A. F., Attisano, L. and Wrana, J. L. (1998) SARA, a FYVE domain protein that recruits Smad2 to the TGFβ receptor. Cell 95, 779-791.
67. 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim. Biophys. Acta 1137, 189-196.
68. Wang, J., Sun, L., Myeroff, L., Wang, X., Gentry, L. E., Yang, J., Liang, J., Zborowska, E., Markowitz, S., Willson, J. K. and Brattain, M. G. (1995) Demonstration that mutation of the type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J. Biol. Chem. 270, 22044-22049.
69. 1 arrest pathway. Mol. Cell. Biol. 19, 5913-5922.
70. Wojtowicz-Praga, S. (1997) Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J. Immunother. 20, 165-177.
71. Won, J., Kim, H., Park, E. J., Hong, Y., Kim, S. J. and Yun, Y. (1999) Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res. 59, 1273-1277.
72. Xu, L., Kang, Y., Col, S. and Massague, J. (2002) Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGFβ signaling complexes in the cytoplasm and nucleus. Mol. Cell 10, 271-282.
73. Yang, X., Chen, L., Xu, X., Li, C., Huang, C. and Deng, C. X. (2001) TGF-ß/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J. Cell Biol. 153, 35-46.
74. Yang, X., Letterio, J. J., Lechleider, R. J., Chen, L., Hayman, R., Gu, H., Roberts, A. B. and Deng, C. (1999) Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. Embo J. 18, 1280-1291.
75. Yuan, W. and Varga, J. (2001) Transforming growth factor-repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J. Biol. Chem. 276, 38502-38510.